Join
Live feed
·
INSIDERFilingvia Quantisnow
Mersana Therapeutics Inc. logo

SVP, Chief Development Officer Bala Mohan converted options into 8,750 shares and sold $2,147 worth of shares (3,253 units at $0.66), increasing direct ownership by 10% to 60,228 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MRSN (Mersana Therapeutics Inc.) and more on Quantisnow.